{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,7]],"date-time":"2026-05-07T08:16:22Z","timestamp":1778141782387,"version":"3.51.4"},"reference-count":33,"publisher":"Informa UK Limited","content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Neurodegenerative Disease Management"],"DOI":"10.1080\/17582024.2026.2667432","type":"journal-article","created":{"date-parts":[[2026,5,7]],"date-time":"2026-05-07T08:01:18Z","timestamp":1778140878000},"page":"1-6","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":0,"title":["Baseline epidemiological differences between donanemab and lecanemab users in real-world settings: a retrospective cohort study"],"prefix":"10.1080","author":[{"given":"Filipi Fim","family":"Andre\u00e3o","sequence":"first","affiliation":[{"name":"Federal University of Rio de Janeiro","place":["Rio de Janeiro, Brazil"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rebeca Oliveira","family":"da Silva","sequence":"additional","affiliation":[{"name":"Federal University of Para\u00edba","place":["Jo\u00e3o Pessoa, Brazil"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria Fernanda Liphaus Almeida","family":"Negreli","sequence":"additional","affiliation":[{"name":"Federal University of Minas Gerais (UFMG)","place":["Belo Horizonte, Brazil"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ana Beatriz P.","family":"Aguiar-Barros","sequence":"additional","affiliation":[{"name":"Cesmac University Center","place":["Macei\u00f3, Brazil"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Diogo Haddad","family":"Santos","sequence":"additional","affiliation":[{"name":"Hospital Alem\u00e3o Oswaldo Cruz","place":["S\u00e3o Paulo, Brazil"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2026,5,7]]},"reference":[{"issue":"23","key":"e_1_3_8_3_1","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1056\/NEJM198006053022305","article-title":"Amyloid deposits and amyloidosis. The beta-fibrilloses (first of two parts)","volume":"302","author":"Selkoe DJ.","year":"1980","unstructured":"Selkoe DJ. Amyloid deposits and amyloidosis. The beta-fibrilloses (first of two parts). N Engl J Med. 1980;302(23):1283\u20131292.","journal-title":"N Engl J Med"},{"key":"e_1_3_8_4_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198006053022305"},{"issue":"3","key":"e_1_3_8_5_1","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1016\/S0006-291X(84)80190-4","article-title":"Alzheimer\u2019s disease: initial report of the purification and characterization of a novel cerebrovascular amyloid protein","volume":"120","author":"Glenner GG","year":"1984","unstructured":"Glenner GG, Wong CW. Alzheimer\u2019s disease: initial report of the purification and characterization of a novel cerebrovascular amyloid protein. Biochem Biophys Res Commun. 1984;120(3):885\u2013890.","journal-title":"Biochem Biophys Res Commun"},{"key":"e_1_3_8_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/0092-8674(89)90177-3"},{"issue":"8","key":"e_1_3_8_7_1","doi-asserted-by":"crossref","first-page":"4492","DOI":"10.1016\/S0021-9258(19)39590-0","article-title":"The Alzheimer amyloid precursor protein: identification of a stable intermediate in the biosynthetic\/degradative pathway","volume":"265","author":"Oltersdorf T","year":"1990","unstructured":"Oltersdorf T, Ward PJ, Henriksson T, et al. The Alzheimer amyloid precursor protein: identification of a stable intermediate in the biosynthetic\/degradative pathway. J Biol Chem. 1990;265(8):4492\u20134497.","journal-title":"J Biol Chem"},{"key":"e_1_3_8_8_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.2111583"},{"key":"e_1_3_8_9_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.1072994"},{"key":"e_1_3_8_10_1","doi-asserted-by":"publisher","DOI":"10.1038\/22124"},{"key":"e_1_3_8_11_1","doi-asserted-by":"publisher","DOI":"10.1038\/78682"},{"issue":"15","key":"e_1_3_8_12_1","doi-asserted-by":"crossref","first-page":"8850","DOI":"10.1073\/pnas.151261398","article-title":"Peripheral anti-A beta antibody alters CNS and plasma a beta clearance and decreases brain a beta burden in a mouse model of Alzheimer\u2019s disease","volume":"98","author":"DeMattos RB","year":"2001","unstructured":"DeMattos RB, Bales KR, Cummins DJ, et al. Peripheral anti-A beta antibody alters CNS and plasma a beta clearance and decreases brain a beta burden in a mouse model of Alzheimer\u2019s disease. Proc Natl Acad Sci USA. 2001;98(15):8850\u20138855.","journal-title":"Proc Natl Acad Sci USA"},{"key":"e_1_3_8_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.arr.2024.102203"},{"key":"e_1_3_8_14_1","doi-asserted-by":"publisher","DOI":"10.1523\/ENEURO.0088-24.2024"},{"key":"e_1_3_8_15_1","doi-asserted-by":"publisher","DOI":"10.1177\/30495334251376614"},{"key":"e_1_3_8_16_1","doi-asserted-by":"publisher","DOI":"10.11477\/mf.030126030530051000"},{"key":"e_1_3_8_17_1","doi-asserted-by":"publisher","DOI":"10.11477\/mf.030126030530050943"},{"key":"e_1_3_8_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2025.178187"},{"key":"e_1_3_8_19_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2023.13239"},{"key":"e_1_3_8_20_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2212948"},{"key":"e_1_3_8_21_1","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2023.1158485"},{"issue":"2","key":"e_1_3_8_22_1","first-page":"123","article-title":"Pathophysiologic mechanisms and safety of amyloid-targeting therapies","volume":"38","author":"Roytman M","year":"2024","unstructured":"Roytman M. Pathophysiologic mechanisms and safety of amyloid-targeting therapies. CNS Drugs. 2024;38(2):123\u2013136.","journal-title":"CNS Drugs"},{"key":"e_1_3_8_23_1","volume-title":"Lecanemab-irmb (LEQEMBI\u00ae) prescribing information","author":"Eisai Inc","year":"2023","unstructured":"Eisai Inc. Lecanemab-irmb (LEQEMBI\u00ae) prescribing information. Woodcliff Lake, NJ, USA; 2023."},{"key":"e_1_3_8_24_1","volume-title":"Donanemab-azbt prescribing information (Kisunla)","author":"Eli Lilly and Company (Lilly USA, LLC)","year":"2024","unstructured":"Eli Lilly and Company (Lilly USA, LLC). Donanemab-azbt prescribing information (Kisunla). Indianapolis, Indiana: U.S. Food and Drug Administration; 2024."},{"key":"e_1_3_8_25_1","doi-asserted-by":"publisher","DOI":"10.14283\/jpad.2022.21"},{"key":"e_1_3_8_26_1","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awad188"},{"issue":"1","key":"e_1_3_8_27_1","first-page":"9","article-title":"CLARITY-AD clinical trial results","volume":"388","author":"van Dyck CH","year":"2023","unstructured":"van Dyck CH. CLARITY-AD clinical trial results. N Engl J Med. 2023;388(1):9\u201321.","journal-title":"N Engl J Med"},{"issue":"8","key":"e_1_3_8_28_1","first-page":"341","article-title":"Cerebral amyloid angiopathy and risk of ARIA","volume":"101","author":"Sveikata L","year":"2023","unstructured":"Sveikata L. Cerebral amyloid angiopathy and risk of ARIA. Neurology. 2023;101(8):341\u2013352.","journal-title":"Neurology"},{"issue":"2","key":"e_1_3_8_29_1","first-page":"481","article-title":"APOE \u03b54 and ARIA risk in amyloid antibody therapy","volume":"92","author":"Foley P","year":"2024","unstructured":"Foley P, Wilcock DM. APOE \u03b54 and ARIA risk in amyloid antibody therapy. J Alzheimers Dis. 2024;92(2):481\u2013494.","journal-title":"J Alzheimers Dis"},{"issue":"9","key":"e_1_3_8_30_1","first-page":"1527","article-title":"Appropriate use recommendations for lecanemab and donanemab","volume":"19","author":"Cummings JL","year":"2023","unstructured":"Cummings JL. Appropriate use recommendations for lecanemab and donanemab. Alzheimers Dement. 2023;19(9):1527\u20131540.","journal-title":"Alzheimers Dement"},{"issue":"2","key":"e_1_3_8_31_1","first-page":"87","article-title":"Patient communication and risk management in amyloid-targeting therapy","volume":"11","author":"Rentz DM","year":"2024","unstructured":"Rentz DM. Patient communication and risk management in amyloid-targeting therapy. J Prev Alzheimers Dis. 2024;11(2):87\u201395.","journal-title":"J Prev Alzheimers Dis"},{"issue":"4","key":"e_1_3_8_32_1","first-page":"1002","article-title":"Cerebrovascular safety and amyloid clearance therapies","volume":"55","author":"Bilodeau M","year":"2024","unstructured":"Bilodeau M. Cerebrovascular safety and amyloid clearance therapies. Stroke. 2024;55(4):1002\u20131013.","journal-title":"Stroke"},{"key":"e_1_3_8_33_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2025.178187"},{"key":"e_1_3_8_34_1","volume-title":"Amyloid-targeting therapy monitoring guidelines","author":"U.S. Food and Drug Administration","year":"2023","unstructured":"U.S. Food and Drug Administration. Amyloid-targeting therapy monitoring guidelines. Silver Spring, Maryland: U.S. Food and Drug Administration; 2023."},{"issue":"7","key":"e_1_3_8_35_1","first-page":"1301","article-title":"Clinical implications of ARIA and MRI monitoring","volume":"19","author":"Cummings JL","year":"2023","unstructured":"Cummings JL. Clinical implications of ARIA and MRI monitoring. Alzheimers Dement. 2023;19(7):1301\u20131312.","journal-title":"Alzheimers Dement"}],"container-title":["Neurodegenerative Disease Management"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/17582024.2026.2667432","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,7]],"date-time":"2026-05-07T08:01:21Z","timestamp":1778140881000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/17582024.2026.2667432"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,7]]},"references-count":33,"alternative-id":["10.1080\/17582024.2026.2667432"],"URL":"https:\/\/doi.org\/10.1080\/17582024.2026.2667432","relation":{},"ISSN":["1758-2024","1758-2032"],"issn-type":[{"value":"1758-2024","type":"print"},{"value":"1758-2032","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,7]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=inmt20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=inmt20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2025-12-01","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-04-16","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-05-07","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}